Please wait while the formulary information is being retrieved.
BAQSIMI (glucagon)
- Hypoglycemic disorder
3 mg/actuation nasal spray
- Spray 1 spray (3 mg) into one nostril by intranasal route once may repeat dose in 15 minutes if inadequate response
Hypoglycemic disorder
- Spray 3 mg into one nostril by intranasal route once may repeat dose in 15 minutes if inadequate response
- Spray 1 spray (3 mg) into one nostril by intranasal route once may repeat dose in 15 minutes if inadequate response
- None
Contraindicated
- None
Severe
Moderate
- None
- Insulinoma
- Pheochromocytoma
Contraindicated
- Glucagonoma
Severe
Moderate
- None
BAQSIMI (glucagon)
- Hypoglycemic disorder
- None
- Cough
- Epistaxis
- Eye tearing
- Headache disorder
- Nasal congestion
- Nasal pain
- Nasal passage irritation
- Nausea
- Ocular itching
- Ocular redness
- Pharyngitis
- Rhinorrhea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Ear itching
- Sneezing
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Hypertension
- Hypotension
Less Severe
- Dysgeusia
- Parosmia
- Pruritus of skin
- Skin rash
- Tachycardia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Glucagon (Nasal)
Safety and effectiveness not established in age < 4 years.
- 1 Day – 4 Years
- Safety and effectiveness not established in age < 4 years.
Glucagon
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
Glucagon
Minimal risk to infant;Short half-life, drug destroyed in gi tract
General | Excretion Potential | Effect on Infant | Notes |
No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Minimal risk to infant;Short half-life, drug destroyed in gi tract |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Hypoglycemic disorder | |
E08.64 | Diabetes mellitus due to underlying condition with hypoglycemia |
E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
E09.64 | Drug or chemical induced diabetes mellitus with hypoglycemia |
E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
E10.64 | Type 1 diabetes mellitus with hypoglycemia |
E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma |
E11.64 | Type 2 diabetes mellitus with hypoglycemia |
E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma |
E13.64 | Other specified diabetes mellitus with hypoglycemia |
E13.649 | Other specified diabetes mellitus with hypoglycemia without coma |
E16.0 | Drug-induced hypoglycemia without coma |
E16.1 | Other hypoglycemia |
E16.2 | Hypoglycemia, unspecified |
P70.3 | Iatrogenic neonatal hypoglycemia |
P70.4 | Other neonatal hypoglycemia |
0-9 | A-Z |
---|---|
E08.64 | Diabetes mellitus due to underlying condition with hypoglycemia |
E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
E09.64 | Drug or chemical induced diabetes mellitus with hypoglycemia |
E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
E10.64 | Type 1 diabetes mellitus with hypoglycemia |
E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma |
E11.64 | Type 2 diabetes mellitus with hypoglycemia |
E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma |
E13.64 | Other specified diabetes mellitus with hypoglycemia |
E13.649 | Other specified diabetes mellitus with hypoglycemia without coma |
E16.0 | Drug-induced hypoglycemia without coma |
E16.1 | Other hypoglycemia |
E16.2 | Hypoglycemia, unspecified |
P70.3 | Iatrogenic neonatal hypoglycemia |
P70.4 | Other neonatal hypoglycemia |
Formulary Reference Tool